Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Utilizing Dividend Yield to Earn Monthly Income from Eli Lillys Stock

Elaine Mendonca by Elaine Mendonca
February 5, 2024
in Breaking News
0
Pharmaceutical Trading online
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

On February 5, 2024, investors looking to earn a monthly income of $500 from Eli Lilly’s stock can utilize the dividend yield. Eli Lilly currently offers an annual dividend yield of 0.78%, which translates to a quarterly dividend of $1.30 per share ($5.20 per year).

To determine the number of shares required to achieve the desired monthly income, divide the annual income by the dividend amount. In this case, the calculation would be $6,000 divided by $5.20, resulting in approximately 1,154 shares. Therefore, to earn $500 per month from Eli Lilly’s stock, an investment of around $770,468 or approximately 1,154 shares would be necessary.

It is important to note that the dividend yield can vary as both the dividend payment and the stock price fluctuate over time. Investors should be mindful of this and understand that the dividend yield is calculated by dividing the annual dividend per share by the current market share price, expressed as a percentage.

Investors should also consider that dividend yield rates that are exceptionally high are often unsustainable. It is crucial to evaluate the stability and reliability of the company’s dividend payments before making any investment decisions.

Strong Performance of Eli Lilly and Company (LLY) in Stock Market Signals Positive Outlook for Investors

On February 5, 2024, Eli Lilly and Company (LLY) showcased an impressive performance in the stock market. According to data sourced from CNN Money, LLY was trading near the top of its 52-week range and above its 200-day simple moving average, indicating a strong upward momentum.

LLY opened at $689.16 on February 5, which was $21.51 higher than its previous close. This substantial gap between the opening and closing prices indicated a strong demand for LLY shares at the beginning of the trading day.

The fact that LLY was trading near the top of its 52-week range further emphasized the stock’s strength.

Additionally, LLY was trading above its 200-day simple moving average, which is a commonly used technical indicator.

Overall, LLY exhibited an impressive performance on February 5, 2024. The stock’s significant price increase, high opening price, and its position near the top of its 52-week range and above its 200-day simple moving average all pointed towards a positive outlook for LLY. Investors and analysts were likely optimistic about the company’s future prospects, making LLY a stock to watch in the pharmaceutical industry.

Analyzing LLY Stock Performance on February 5, 2024: Revenue Growth, Net Income Decline, and EPS Concerns

LLY Stock Performance on February 5, 2024: A Closer Look

On February 5, 2024, Eli Lilly and Company (LLY) saw its stock performance come under scrutiny as investors analyzed the company’s financial data. Using information sourced from CNN Money, we can delve into the key figures that shaped LLY’s performance on that day.

Total revenue for the past year stood at $28.54 billion, with a quarterly total revenue of $9.50 billion. The total revenue remained flat compared to the previous year but experienced a notable increase of 14.27% since the previous quarter.

Net income over the past year was $6.24 billion, while in the most recent quarter, it recorded a net loss of -$57.40 million. LLY’s net income increased by 11.88% compared to the previous year. However, the recent quarter’s net income decline of 103.26% should raise concerns among investors.

Earnings per share (EPS) for the past year stood at $6.90, while in the most recent quarter, it reported a negative EPS of -$0.06. LLY experienced a positive growth in EPS of 12.75% compared to the previous year. However, the EPS decline of 103.27% in the last quarter is concerning.

LLY’s stock performance on February 5, 2024, faced challenges in the most recent quarter. While total revenue showed promising growth, the net income and EPS figures raised concerns among investors. The decline in net income and EPS can be attributed to various factors, such as increased expenses, lower sales, or one-time charges.

Investors should closely monitor LLY’s financial reports and news updates to gain a deeper understanding of the reasons behind the recent decline in net income and EPS. It is crucial to evaluate whether these figures are indicative of a short-term setback or a more significant issue that may impact the company’s long-term prospects.

As with any investment, it is essential to conduct thorough research and seek advice from financial professionals before making any decisions based on stock performance. The figures mentioned above provide a snapshot of LLY’s performance on February 5, 2024, but it is crucial to consider additional factors and trends to make informed investment choices.

Tags: LLY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Renewable energy

Barclays Analyst Reiterates EqualWeight Rating on Ormat Technologies with Revised Price Target

Supernus Pharmaceuticals Wins Patent Infringement Case Secures Exclusivity for Trokendi XR

Finance_Cash

Goldman Sachs Raises Price Target and Adds NVIDIA to Conviction List

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com